Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: Results from a real-life screening programme

K Morrisroe; W Stevens; J Sahhar; C Rabusa; M Nikpour; S Proudman; C Hill; S Lester; M Rischmueller; J Walker; P Nash; G Ngian; J Roddy; G Strickland; V Thakkar; J Zochling

Journal article

Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: Results from a real-life screening programme

K Morrisroe, W Stevens, J Sahhar, C Rabusa, M Nikpour, S Proudman, C Hill, S Lester, M Rischmueller, J Walker, P Nash, G Ngian, J Roddy, G Strickland, V Thakkar, J Zochling

Arthritis Research and Therapy | BMC | Published : 2017

DOI: 10.1186/s13075-017-1250-z

Download PDF

Abstract

Background: Pulmonary arterial hypertension (PAH) is the leading cause of death in systemic sclerosis (SSc). Annual screening with echocardiogram (ECHO) is recommended. We present the methodological aspects of a PAH screening programme in a large Australian SSc cohort, the epidemiology of SSc-PAH in this cohort, and an evaluation of factors influencing physician adherence to PAH screening guidelines. Methods: Patient characteristics and results of PAH screening were determined in all patients enrolled in a SSc longitudinal cohort study. Adherence to PAH screening guidelines was assessed by a survey of Australian rheumatologists. Summary statistics, chi-square tests, univariate and multivaria..

View full abstract

University of Melbourne Researchers

Wendy Stevens Author

Mandana Nikpour Author

Katie Morrisroe Author

Related Projects (2)

IMPROVING OUTCOMES IN SYSTEMIC AUTOIMMUNE DISEASE: A COLLABORATIVE AND INTERDISCIPLINARY PROGRAM OF RESEARCH

The multi-organ autoimmune diseases ‘scleroderma’ and ‘lupus’ have a profound negative impact on quality of life and life expectancy. The ov..

QUANTIFYING THE BURDEN OF SYSTEMIC SCLEROSIS IN AUSTRALIA: FROM DATA LINKAGE TO PATIENT REPORTED OUTCOMES

Systemic sclerosis (SSc) is a rare autoimmune disease with the potential to cause significant physical, financial and psychosocial burden on..

Grants

Awarded by Pfizer

Funding Acknowledgements

This work was supported by Scleroderma Australia, Arthritis Australia, Actelion Australia, Bayer, CSL Biotherapies, GlaxoSmithKline Australia and Pfizer. Dr Morrisroe holds an NHMRC Scholarship (APP1113954). Dr Nikpour holds an NHMRC Fellowship (APP1071735).